GlassScriptPhysician profile
Jamie Price
NPI 1639946445
$4,336.87
in general payments reported to CMS, 2019-2025
25 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,995 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,336.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.09 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $771.48 | 2024-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $426.15 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $266.82 | 2024-2025 | |
| Novo Nordisk INC | $237.11 | 2024-2025 | Wegovy |
| Amgen INC. | $211.30 | 2024-2025 | Evenity, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.54 | 2024-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $192.13 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $140.25 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.10 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $103.28 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.02 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $93.69 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $84.04 | 2024 | Xarelto |
| Corcept Therapeutics | $61.55 | 2024-2025 | Korlym |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $55.33 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $48.53 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Tactile Systems Technology INC | $44.29 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Boston Scientific Corporation | $41.81 | 2025 | Watchman Flx, Watchman Access System |
| Currax Pharmaceuticals LLC | $33.26 | 2025 | Contrave, Onzetra Xsail |
| Axsome Therapeutics, INC. | $29.16 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $28.64 | 2024-2025 | Eliquis |
| Stryker Corporation | $25.48 | 2025 | Clottriever Bold Catheter |
| Medtronic, INC. | $17.69 | 2025 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $17.13 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.